Evidence map›Paper›PMID 41023764›Full record

ArticleEuropean journal of medical research2025

HMGB1-mediated macrophage polarization to M2 phenotype promotes ureteral stricture: therapeutic potential of HMGB1 inhibitors.

Jie Zheng, Lingsong Tao, Yingqing Liu, Yang Zhang, Li Cheng, Zongyao Hao

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie ZhengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University; Institute of Urology, Anhui Medical University; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Hefei City, Anhui Province, China.
Lingsong TaoDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu City, Anhui Province, China.
Yingqing LiuDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu City, Anhui Province, China.
Yang ZhangWannan Medical College Clinical Medicine Experimental and Training Center, Wuhu City, Anhui Province, China.
Li ChengDepartment of Urology, The Second People's Hospital of Wuhu, Wuhu City, Anhui Province, China.
Zongyao HaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University; Institute of Urology, Anhui Medical University; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Hefei City, Anhui Province, China. haozongyao@163.com.

Funding

the Translational Medicine Research Foundation of Anhui Province 2021zhyx-B08
6 · The paper itself

Abstract

backgroundUreteral stricture is a common condition characterized by fibrotic narrowing of the ureter, often resulting in obstruction and impaired renal function. The condition is typically associated with chronic inflammation, epithelial injury, and abnormal wound healing responses, leading to excessive deposition of extracellular matrix proteins. High Mobility Group Box 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, plays a key role in promoting inflammation and fibrosis in various tissues. However, its specific role in the pathogenesis of ureteral stricture remains unclear. Glycyrrhizin, a natural HMGB1 inhibitor, has shown therapeutic potential in alleviating inflammation and fibrosis in preclinical studies of other fibrotic diseases. This study explores the involvement of HMGB1 in ureteral fibrosis and evaluates the efficacy of glycyrrhizin as a potential therapeutic agent. PATIENTS AND

methodsUreteral tissue samples were collected from seven patients with ureteral stricture, and a rabbit model of ureteral stricture was established using thermal injury to the left ureter. HMGB1 expression in both human and rabbit tissues was analyzed via Western blot. SV-HUC-1 cells were subjected to three distinct injury models: UVB irradiation, radiotherapy, and chemotherapy with cisplatin, to simulate ureteral damage and assess HMGB1 secretion and localization. THP-1 macrophages were treated with recombinant HMGB1 or conditioned medium from injured SV-HUC-1 cells, and macrophage polarization was evaluated using flow cytometry, with IL-4 stimulation serving as a positive control. The role of macrophage polarization in fibroblast activation was investigated using conditioned medium to treat MRC-5 fibroblasts, followed by Western blot and qPCR to measure the expression of activation markers. The impact of the TGF-β inhibitor SB-431542 on fibroblast activation was also assessed. Glycyrrhizin's therapeutic effects and toxicity were evaluated in vitro through biochemical assays and in vivo by histological analysis in rabbit models.

resultsHMGB1 levels were significantly elevated in fibrotic segments of ureteral tissues from both patients and rabbit models. In SV-HUC-1 cells, injury induced HMGB1 translocation from the nucleus to the cytoplasm and extracellular medium. Conditioned medium from injured SV-HUC-1 cells and direct exposure of THP-1 macrophages to recombinant HMGB1 protein both stimulated M2 polarization of macrophages, which secreted TGF-β and activated fibroblasts to upregulate α-SMA, FAP, FN1, and COL1A1. In contrast, direct exposure of fibroblasts to recombinant HMGB1 showed minimal effects on these markers, suggesting an indirect mechanism mediated by macrophages. Treatment with the TGF-β inhibitor SB-431542 effectively suppressed fibroblast activation induced by HMGB1-conditioned medium from macrophages, confirming the critical role of TGF-β in this pathway. Glycyrrhizin effectively inhibited HMGB1-induced macrophage polarization and fibroblast activation in vitro and improved ureteral stricture and hydronephrosis in the rabbit model without detectable toxicity.

conclusionHMGB1 contributes to ureteral stricture by promoting macrophage polarization and fibroblast activation, leading to extracellular matrix accumulation and fibrosis. Glycyrrhizin effectively inhibits these processes and alleviates ureteral stricture, demonstrating its potential as a therapeutic agent for ureteral fibrosis. These findings provide a basis for further exploration of HMGB1-targeted therapies.

Indexed as

Glycyrrhizic AcidHMGB1 ProteinMacrophagesUreteral ObstructionAnimalsDisease Models, AnimalFemaleFibrosisHumansMaleMiddle AgedPhenotypeRabbitsGlycyrrhizic AcidHMGB1 ProteinHMGB1 protein, humanFibroblast activationGlycyrrhizinHMGB1Macrophage polarizationTGF-βUreteral stricture

Identifiers

PMID41023764
PMCPMC12481876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.